The objective of the FLIGHT3 study was to evaluate the long-term safety and efficacy of indacaterol/ glycopyrrolate* (IND/GLY) versus an active comparator, IND, in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) over 52 weeks. Method: FLIGHT3 was a multicenter, randomized, double-blind, parallel-group, 52-week study. Results: A total of 85.2% patients completed the study treatment. The overall incidence of AEs (and SAEs) was similar between treatments. Major adverse cardiovascular events (MACE) and/or cardiovascular (CV) events were comparable between treatment groups. The rate of discontinuation of the study treatment due to AEs was lower for IND/GLY than IND. Improvements in pre-dose trough FEV1 and post-dose 1-h FEV1 were consistently superior with IND/GLY than with IND over 52 weeks, demonstrating long-term maintenance of lung function. Conclusions: IND/GLY demonstrated a favorable long-term safety and tolerability profile and provided effective bronchodilation, with maintenance of lung function over 52 weeks in patients with moderate-to-severe COPD. These data support the safety and efficacy of IND/GLY as a treatment option for COPD. 
Chronic obstructive pulmonary disease (COPD) is a progressive debilitating respiratory condition characterized by respiratory symptoms with persistent and progressive airflow limitation.
1 It is a major cause of poor health and death worldwide and contributes significantly to health care costs and comorbidity.
2-4
COPD remains a significant public health challenge and is one of the leading causes of morbidity and mortality in the United States, affecting an estimated 27 million Americans.
5 It is currently the third leading cause of death in the United States and claimed 134,676 lives in 2010. 6 It results in 1.5 million visits to emergency departments, over 15 million physician visits every year and 739,000 hospitalizations.
7,8
COPD is a treatable disease. However, due to the heterogeneity of the disease and its response to current therapies, new therapeutic options are needed. Current COPD treatment guidelines recommend the use of one or more bronchodilators, depending on the severity of patients' airflow limitations, history of exacerbations, and symptoms.
1 Inhaled bronchodilator therapies, such as selective beta2-adrenergic receptor agonists and muscarinic receptor antagonists, are widely used treatment options for COPD, as are inhaled corticosteroids (ICS) in combination with a long-acting beta2-agonists (LABA) .
1 Studies have demonstrated that complementary mechanisms of action of a LABA and a long-acting muscarinic antagonist (LAMA) significantly improve bronchodilation in COPD patients compared with the respective monotherapy
Introduction

Methods
Study Design
FLIGHT3 was a multicenter, randomized, doubleblind, parallel-group study that compared safety and components.
9,10 Combining bronchodilators, each with a different mechanism of action to influence airflow limitation, may maximize the bronchodilator response and impact the inter-and intra-patient variability in bronchometer tone associated with COPD.
11,12
In addition, several studies have demonstrated that LABA/LAMA combinations have a better impact on lung function, inspiratory capacity, and quality of life compared with the respective monotherapies.
13-15
Indacaterol maleate/glycopyrrolate (IND/GLY; QVA149) is a fixed-dose combination (FDC) of a LABA (indacaterol [IND] ; QAB149) and a LAMA (glycopyrrolate [GLY] ; NVA237) intended to be used for the long-term maintenance treatment of airflow obstruction in patients with COPD including chronic bronchitis and/or emphysema. The safety and efficacy of both IND and GLY have been demonstrated, with each monocomponent having a safety profile similar to that of a placebo.
16-18
FDC therapy may also offer a potential advantage over monotherapy by increasing treatment adherence through the use of a single inhaler. Patients using multiple inhalers have demonstrated higher risk of exacerbations along with significantly higher health care costs and utilization.
20 IND/GLY provides the opportunity for patients with COPD to receive dual bronchodilator therapy using 1 device, which results in rapid bronchodilation and a sustained efficacy for 12 hours.
21 In December 2013, the Food and Drug Administration (FDA) approved the first dual longacting bronchodilator (Anoro® Ellipta®) for the longterm maintenance treatment of airflow obstruction in patients with COPD including chronic bronchitis and emphysema. Stiolto™ Respimat®, a once-daily (o.d.) FDC of tiotropium and olodaterol, was approved in June 2015 by the FDA for treatment of COPD. In addition, the FDA has recently approved the dual combination (IND/ GLY) Utibron Neohaler™ for the long-term maintenance treatment of airflow obstruction in patients with COPD.
The purpose of the FLIGHT3 study was to demonstrate the long-term safety and tolerability of twice-daily (b.i. 
Patients
The study recruited male and female patients aged ≥40 years who had stable COPD according to the 2011 Global initiative for chronic Obstructive Lung Disease (GOLD) criteria.
1 Patients were included if they had moderate-to-severe airflow limitation, as indicated by post-bronchodilator forced expiratory volume in 1 second (FEV1) ≥30% and <80% of the predicted normal and a post-bronchodilator FEV1/forced vital capacity (FVC) ratio <0.70 at run in. The patients were either current or ex-smokers, with a smoking history of at least 10 pack years, and were symptomatic, as defined by a modified Medical Research Council (mMRC) dyspnea scale, Grade ≥2.
Patients with any history of asthma or concomitant pulmonary disease or with a significant disease other than COPD that could significantly confound the trial results or preclude trial completion (including cardiovascular [CV] , neurological, endocrine, immunological, psychiatric, gastrointestinal, hepatic, or hematological abnormalities) were excluded. Patients were also excluded if they had a COPD exacerbation that required treatment with antibiotics and/or systemic corticosteroids and/or hospitalization in the 6 weeks prior to Visit 1. Further information on exclusion criteria is available in the online supplementary data (eTable 1). All patients provided written informed consent, and all protocols were approved by an ethics committee.
Study Treatments and Randomization
This study comprised a 7-day screening period and a 14-day run-in period, followed by randomization All eligible patients were randomized via Interactive Response Technology (IRT) to one of the treatment groups. Treatment randomization was stratified based on the smoking status, ICS use, and severity of airflow limitation. Patients were instructed to take 1 capsule each morning (between 07:00 and 11:00 h) and 1 in the evening (between 19:00 and 23:00 h). Each patient was provided with a salbutamol/albuterol inhaler, which was permitted for use as rescue medication throughout the study. Nebulized salbutamol/albuterol was not permitted. Patients used an electronic diary (e-diary) to capture the use of rescue medication.
Outcomes and Assessments
The primary objective was to evaluate the safety and tolerability of IND/GLY (27.5/15.6 or 27.5/31.2µg) versus IND (75µg) in terms of adverse event (AE)-reporting rates in patients with moderate-to-severe COPD over 52 weeks. Secondary objectives were to evaluate the bronchodilator effect of IND/GLY (27.5/15.6 A composite endpoint of major adverse cardiovascular events (MACE) was included in the analysis, which represented all serious CCV AEs adjudicated by an independent committee to one of the following categories: a)non-fatal myocardial infarction, b)hospitalization for unstable angina, c)non-fatal stroke, d)heart failure requiring hospitalization, and e) coronary re-vascularization (coronary artery bypass graft or percutaneous coronary intervention).
Particular attention was paid to the LABA and LAMA drug classes in terms of safety variables, such as increased heart rate, increased blood pressure, CCV (major cerebrovascular events, cardiac arrhythmias), 
Results
Patients
Of the 615 patients randomized to treat, 85.2% completed the planned study treatment. One randomized patient in the IND group did not receive the study medication and was excluded from the analysis. Overall, 68 patients discontinued the treatment, with the most frequent reason for discontinuation being patient/guardian decision (n=41) (Figure 1 ). Other reasons for treatment discontinuation included lack of efficacy, protocol deviations, and physician's decision (with comparable rates among treatment groups) (Figure 1 ). Most patients (>99%) were compliant with the study medication per protocol (which categorized compliance as 80%-100%) with a similar rate between hypokalemia, diabetes and hyperglycemia, corrected QT interval prolongation, paradoxical bronchospasm, narrow-angle glaucoma, blurred vision, urinary outflow obstruction, urinary retention, and anticholinergic syndrome.
The change from baseline in pre-dose trough FEV1 from Week 4 to Week 52 was analyzed using a mixedmodel repeated-measures (MMRM) analysis on a full analysis set (FAS; all randomized patients who received at least 1 dose of study medication). This model included treatment, baseline FEV1, visit, treatment by visit interaction, visit by baseline FEV1 interaction, smoking status at baseline, baseline ICS use, airflow limitation severity, and region as fixed effects with unstructured variance-covariance error matrix. Similar analysis was performed for change from baseline in post-dose 1-h FEV1 (as measured at the same visits and at Day 1), predose trough FVC, and post-dose 1-h FVC.
The time to first COPD exacerbation was assessed using Kaplan-Meier curve and analyzed using Cox regression model for the FAS. The rate of COPD exacerbations was analyzed using a generalized linear model assuming a negative binomial distribution. The log (exposure time) was used as an offset variable in the model.
Daily, morning, and evening symptom scores were analyzed using a linear mixed model (LMM). A similar LMM was also used to analyze daily, daytime, and nighttime rescue mediation uses. The change from baseline in COPD assessment test (CAT) total score at Weeks 12, 28, 44, and 52 was analyzed using a similar MMRM as that used for pre-dose trough FEV1, with baseline FEV1 replaced by baseline CAT total score. the twice daily and once daily treatment groups.
Patient demographics were comparable between the 3 treatment groups ( (Table 1) . Since an mMRC score of ≥2 was required for study entry, no Group A or C patients were included. In the year prior to enrollment, only 33% patients had a history of COPD exacerbation ( Table 1 ). Table 2 ). The rate of discontinuation from the study treatment due to AEs was lowest for IND/GLY 27.5/15.6µg (2.5%), followed by IND/GLY 27.5/31.2µg (3.9%) and IND 75µg (5.8%). The 3 treatment groups demonstrated comparable trends when assessing the time to first AEs leading to permanent discontinuation ( Figure 2) . The incidence of drug-related AEs was higher with IND 75µg (9.2%) than that with IND/GLY 27.5/31.2µg (6.9%) or IND/GLY 27.5/15.6µg (4.4%); no specific pattern of drug-related discontinuations was observed.
Outcomes
Adverse Events
The incidence of SAEs was low and comparable between all treatment groups: IND/GLY 27.5/15.6µg, 12.7%; IND/GLY 27.5/31.2µg, 12.3%; and IND 75µg, 11.7% (Table 2) . Similar trends were observed between the treatment groups when assessing the time to first SAE (including COPD exacerbation) (Figure 3) . The rate of discontinuation of the study medication due to SAEs was also low and comparable between all treatment groups (IND/GLY 27.5/15.6µg, 2.0%; IND/ GLY 27.5/31.2µg, 2.5%; IND 75µg, 3.4%).
The incidence of CCV events as a risk category was comparable between IND/GLY 27.5/15.6µg (4.4%) and IND 75µg (4.4%) but was higher with IND/GLY 27.5/31.2µg (7.4%). study drug by the reporting investigator.
No clinically meaningful between-group differences for any clinical chemistry or hematological parameter were observed. ECG parameters did not demonstrate any meaningful between-group differences in the rates of abnormalities seen for Fridericia-corrected QT interval values and other ECG intervals. There was no evidence of a treatment-related effect on vital signs (pulse and systolic and diastolic blood pressures) (see online supplemental data eTables 2 and 3).
Trough FEV1 and FVC
Improvements in pre-dose trough FEV1 with both the IND/GLY doses were consistently superior to those with IND at Week 52 (treatment difference [∆], 80 and 79 mL for IND/GLY 27.5/15.6 and 27.5/31.2µg, respectively) at all visits up to Week 52 (Figure 4[a] ). Improvements in post-dose 1-h FEV1 with IND/GLY 27.5/15.6µg were consistently superior to those with IND 75µg at all visits up to 52 weeks (∆, 44 mL on Day 1; ∆, 108 mL on Day 365) (Figure 4 [b] ). Similarly, predose trough FVC and post-dose 1-h FVC with both the IND/GLY doses were superior to those with IND over 52 weeks (online supplemental data eFigures 1 and 2).
COPD Exacerbation and Patient-reported Endpoints
The number of patients who experienced mild, moderate, or severe COPD exacerbations was comparable among the treatment groups. Both IND/GLY doses resulted in a 12% reduction in the risk of moderate or severe COPD exacerbation compared with IND, although this was not statistically significant (hazard ratio [HR] A majority of symptom score endpoints, use of rescue medication, and CAT scores were similar between the treatment groups (online supplemental data eTables 4 and 5 and eFigure 3).
Discussion
In this 1-year study, the safety and efficacy of IND/ GLY, a b. Although this study was neither designed nor powered as an exacerbation trial with high-risk patients, there were numerical between-group differences in the rate of reduction of moderate or severe COPD exacerbations, with IND/GLY 27.5/15.6µg demonstrating 25% fewer exacerbations as compared with IND 75µg. In addition, both the IND/GLY doses resulted in a 12% reduction in the risk of moderate or severe COPD exacerbations as compared with IND. Although these exacerbation results were not statistically significant, they are suggestive of a possible added therapeutic benefit if an appropriately designed and powered study is to be performed.
There are limitations of this study that have to be acknowledged. This study had no placebo group due to the long-term nature of the study. It was considered unethical to recruit patients with moderate-to-severe COPD in a placebo group for a 52-week duration. No significant difference was observed between IND/GLY 27.5/15.6µg and IND 75µg in terms of exacerbations/ symptoms possibly because both the treatments were highly active, and the study was not powered to demonstrate this.
In conclusion, the FLIGHT3 study demonstrated the long-term safety, tolerability, and sustained efficacy of IND/GLY 27.5/15.6µg b.i.d. in patients with moderateto-severe COPD over 52 weeks of treatment. This data demonstrates that IND/GLY b.i.d. is a safe and welltolerated treatment option for long-term use in patients with COPD.
